Latest Impairment News

Endeavour Group posted a 1.3% rise in FY26 sales to $12.2 billion but underlying profit slipped as it flagged $372 million in significant asset write-downs and restructuring costs.

Credit Corp delivered a 12% profit rise to a record $105.5 million in FY2026, powered by a 57% surge in US debt buying earnings and a strategic entry into UK consumer lending.

EROAD has appointed David Leach as CEO, effective October 2026, aiming to leverage his SaaS scaling expertise to accelerate growth and develop an AI-native platform.

T&G Global has agreed to sell its T&G Fresh business in three transactions worth a combined enterprise value of NZD 72.65 million, aiming to sharpen its focus on premium apples and VentureFruit platforms while reducing debt.

Fortescue Metals Group delivered a record 201.3 million tonnes of iron ore shipments in FY26, maintaining cost control despite inflation and advancing its green energy projects. The company flagged a US$525 million impairment on Iron Bridge but remains focused on decarbonisation and growth.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Perpetual Limited recorded solid growth across its divisions in Q4 FY26, with Corporate Trust and Asset Management buoyed by market gains despite net outflows. The company is advancing the sale of its Wealth Management arm to Bain Capital, targeting completion in late 2026.

Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.

DroneShield has locked in $23.2 million in European military contracts and launched RfAI-3, its advanced RF detection engine, while upgrading FY2026 revenue guidance to $250-$270 million.

Yowie Group has doubled its half-year profit to US$0.9 million amid a 16% revenue decline, driven by a US customer range cut and elevated cocoa costs impacting Australia. The confectionery maker advances its turnaround with new product launches and legal wins, while navigating ongoing funding and legacy loan challenges.